Antipsychotics - Articles - Page 18

Background of the CATIE Trial

February 1, 2006

John Hsiao, MD Project Officer, National Institute of Mental Health Dr. Hsiao has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.

Dr. Hsiao, you were NIMH’s project officer for the CATIE trial. What was your goal when you came up with the idea for CATIE?

What is an “atypical”?

February 1, 2006

Following the introduction of the first neuroleptics in the 1950s, pharmaceutical companies continued screening compounds for psychoactive properties. In 1959, at Wander Laboratories (ultimately purchased by Sandoz), researchers were surprised to discover a chemical similar to tricyclic antidepressants that had antipsychotic properties. They named it clozapine.

Philip G. Janicak, M.D. On Using Atypical Antipsychotics

February 1, 2005

Philip G. Janicak, M.D.

Philip G. Janicak, M.D. Professor of Psychiatry, Rush University Medical Center Dr. Janicak has disclosed that he is a member of the speakers bureau of Abbott, Astra-Zeneca, Bristol-Myers Squibb, Janssen, and Pfizer, that he is a consultant for Astra-Zeneca, Bristol-Myers Squibb, Janssen, and Pfizer, and that he has received grant/research support from Astra-Zeneca, Bristol-Myers Squibb, Janssen, Neuronetics, and Sanofi-Synthelabo. Dr. Janicak has disclosed that propranolol has not been approved by the U.S. Food and Drug Administration for use in the treatment of agitation. Please consult product labeling for the approved usage.

Dr. Janicak, you've had a long career in research and academia, and I was hoping you could help shed some light on the various contentious issues surrounding the use of atypical antipsychotics, including the issue of whether there is clearly a difference in metabolic profile among the different medications.

Antipsychotic Updates

February 1, 2004

Daniel Carlat, MD

Daniel Carlat, MD Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.

Tired of industry-funded antipsychotic trials? The NIMH comes to the rescue with the "CATIE" project (Clinical Antipsychotic Trials of Intervention Effectiveness). Blissfully un-industry-funded researchers have enrolled 1500 schizophrenic patients at 50 different sites, and have randomly assigned them to Zyprexa, Seroquel, Risperdal, Geodon, or Trilafon (perphenazine).